Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018

Details for Mechanism ID: 17855
Country/Region: Uganda
Year: 2016
Main Partner: RTI International
Main Partner Program: NA
Organizational Type: Private Contractor
Funding Agency: USDOD
Total Funding: $2,359,499 Additional Pipeline Funding: $421,236

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $445,563
Care: Orphans and Vulnerable Children (HKID) $42,304
Care: TB/HIV (HVTB) $113,736
Care: Pediatric Care and Support (PDCS) $254,319
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $280,727
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $206,157
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $75,329
Treatment: Adult Treatment (HTXS) $873,237
Treatment: Pediatric Treatment (PDTX) $68,127
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV Age/Sex: <10 Female 2017 27
GEND_GBV Age/Sex: <10 Male 2017 16
GEND_GBV Age/Sex: 10-14 Female 2017 76
GEND_GBV Age/Sex: 10-14 Male 2017 16
GEND_GBV Age/Sex: 15-19 Female 2017 135
GEND_GBV Age/Sex: 15-19 male 2017 28
GEND_GBV Age/Sex: 20-24 Female 2017 135
GEND_GBV Age/Sex: 20-24 Male 2017 27
GEND_GBV Age/Sex: 25-49 Female 2017 54
GEND_GBV Age/Sex: 25-49 Male 2017 27
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 49
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 119
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 422
GEND_GBV Number of people receiving post-GBV care 2017 541
GEND_GBV Sum of Age/Sex Disaggregates 2017 135
HTS_TST Age/sex: <1 2017 996
HTS_TST Age/sex: 1-9 2017 3,286
HTS_TST Age/sex: 10-14 Female 2017 2,839
HTS_TST Age/sex: 10-14 Male 2017 2,837
HTS_TST Age/sex: 15-19 Female 2017 5,779
HTS_TST Age/sex: 15-19 Male 2017 10,678
HTS_TST Age/sex: 20-24 Female 2017 8,668
HTS_TST Age/sex: 20-24 Male 2017 16,018
HTS_TST Age/sex: 25-49 Female 2017 13,291
HTS_TST Age/sex: 25-49 Male 2017 24,560
HTS_TST Age/sex: 50+ Female 2017 1,156
HTS_TST Age/sex: 50+ Male 2017 2,136
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 4,980
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 4,978
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 28,894
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 53,392
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 92,244
HTS_TST Service Delivery Point (Facility): Index testing 2017 2,126
HTS_TST Service Delivery Point (Facility): Inpatient 2017 27,183
HTS_TST Service Delivery Point (Facility): Other PITC 2017 6,907
HTS_TST Service Delivery Point (Facility): Outpatient 2017 27,862
HTS_TST Service Delivery Point (Facility): Pediatric 2017 9,958
HTS_TST Service Delivery Point (Facility): PMTCT 2017 681
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 680
HTS_TST Service Delivery Point (Facility): VMMC 2017 16,847
HTS_TST Sum of Age/Sex disaggregates 2017 87,962
HTS_TST Sum of Aggregated Age/Sex <15 2017 9,958
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 82,286
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 92,244
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 179
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 178
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 453
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 411
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 680
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 617
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 1,043
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 946
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 91
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 83
HTS_TST_POS Test Result by Age: Positive: <1 2017 63
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 206
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 313
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 313
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,267
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,057
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 435
OVC_SERV Age/Sex: 18+ Female 2017 539
OVC_SERV Age/Sex: 18+ Male 2017 445
OVC_SERV By Aggregated Age/Sex: <18 Female 2017 1,538
OVC_SERV By Aggregated Age/Sex: <18 Male 2017 1,438
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2017 3,960
OVC_SERV Sum of Age/Sex disaggregates 2017 984
PMTCT_ART Already on ART at beginning of current pregnancy 2017 355
PMTCT_ART New on ART 2017 702
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 7,610
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 247
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 69
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 3
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 12
PMTCT_EID Sum of Infant Age disaggregates 2017 316
PMTCT_STAT By: Known positives at entry 2017 395
PMTCT_STAT By: Number of new positives identified 2017 660
PMTCT_STAT Number of new ANC and L&D clients 2017 8,010
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 7,610
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,055
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 15
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 366
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 20
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 662
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,063
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,063
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,893
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 189
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 568
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 1,136
TB_SCREENDX Screen Result: Screened Positive for TB 2017 473
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 14,042
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 7,231
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 1,422
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 968
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 23,663
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 23
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 318
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 31
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 579
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 951
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 951
TX_CURR Age/Sex: <1 2017 96
TX_CURR Age/Sex: <1-9 2017 569
TX_CURR Age/Sex: 10-14 Female 2017 1,038
TX_CURR Age/Sex: 10-14 Male 2017 687
TX_CURR Age/Sex: 15-19 Female 2017 702
TX_CURR Age/Sex: 15-19 Male 2017 217
TX_CURR Age/Sex: 20-24 Female 2017 3,230
TX_CURR Age/Sex: 20-24 Male 2017 1,446
TX_CURR Age/Sex: 25-49 Female 2017 9,408
TX_CURR Age/Sex: 25-49 Male 2017 5,206
TX_CURR Age/Sex: 50+ Female 2017 702
TX_CURR Age/Sex: 50+ Male 2017 362
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,422
TX_CURR Aggregated Age/Sex: <15 Male 2017 968
TX_CURR Aggregated Age/Sex: 15+ Female 2017 14,042
TX_CURR Aggregated Age/Sex: 15+ Male 2017 7,231
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 23,663
TX_CURR Sum of age/sex disaggregates 2017 919
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,390
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 21,273
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 23,663
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 633
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 562
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 5,667
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 2,920
TX_NEW By Age/Sex: <1 2017 47
TX_NEW By Age/Sex: 1-9 2017 287
TX_NEW By Age/Sex: 10-14 Female 2017 462
TX_NEW By Age/Sex: 10-14 Male 2017 399
TX_NEW By Age/Sex: 15-19 Female 2017 283
TX_NEW By Age/Sex: 15-19 Male 2017 88
TX_NEW By Age/Sex: 20-24 Female 2017 1,303
TX_NEW By Age/Sex: 20-24 Male 2017 584
TX_NEW By Age/Sex: 25-49 Female 2017 3,797
TX_NEW By Age/Sex: 25-49 Male 2017 2,102
TX_NEW By Age/Sex: 50+ Female 2017 284
TX_NEW By Age/Sex: 50+ Male 2017 146
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 9,782
TX_NEW Sum of Age/Sex disaggregates 2017 9,448
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 9,782
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 18,930
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 17,037
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,023
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 697
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 10,106
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 5,211
TX_PVLS Numerator: Indication: Routine 2017 17,037
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,137
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 774
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 11,231
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 5,788
TX_PVLS_den Denominator: Indication: Routine 2017 18,930
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 27
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 36
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 44
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 42
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 53
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 192
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 559
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,274
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 42
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 431
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 49
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 62
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 835
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,769
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,715
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,050
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 31
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 40
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 49
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 47
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 60
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 216
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 398
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 628
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,431
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 46
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 99
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 55
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 70
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 937
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,988
VMMC_CIRC By Age: 10-14 2017 6,570
VMMC_CIRC By Age: 15-19 2017 4,886
VMMC_CIRC By Age: 20-24 2017 2,359
VMMC_CIRC By Age: 25-29 2017 1,348
VMMC_CIRC By Age: 30-49 2017 1,348
VMMC_CIRC By Age: 50+ 2017 336
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 16,847
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 16,847
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 16,847
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 14,151